1 terminated. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Terminated 1 |
Follow trilaciclib: new trials by email Literature Review of trilaciclib trials Research Report on trilaciclib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC): Trilaciclib, Placebo - Colorectal Cancer Metastatic, Myelosuppression-Adult | Phase 3 | Terminated | G1 Therapeutics, Inc. | 326 | 2021-01-06 | 2024-11-26 |
China (1) · Hungary (1) · Italy (1) · Poland (1) · Spain (1) · Ukraine (1) · United Kingdom (1) · United States (1)